UBS downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of DKK 340, down from DKK 600. The firm sees “challenging times” for the company with its analysis indicating U.S. compounding of weight loss drugs is “here to stay.” This leaves an uncertain outlook for Novo’s Wegovy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Faces Legal Storm Over Misleading Projections
- Novo Nordisk Receives Unsolicited Mini-Tender Offer from TRC Capital
- Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
- Options Volatility and Implied Earnings Moves This Week, August 04 – August 08, 2025
- Is NVO a Buy, Before Earnings?